RAD51D and breast cancer: The association between RAD51D GPVs and ER-negative BC and TNBC was further confirmed by two large epidemiological studies [22,23], which led to the recent conclusion that RAD51D is a moderate-risk gene with a lifetime risk of developing BC of 15–40% [24].